171 related articles for article (PubMed ID: 21401851)
1. Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential.
Torekov SS; Madsbad S; Holst JJ
Obes Rev; 2011 Aug; 12(8):593-601. PubMed ID: 21401851
[TBL] [Abstract][Full Text] [Related]
2. Gastric bypass surgery: improving psoriasis through a GLP-1-dependent mechanism?
Faurschou A; Zachariae C; Skov L; Vilsbøll T; Knop FK
Med Hypotheses; 2011 Dec; 77(6):1098-101. PubMed ID: 21968278
[TBL] [Abstract][Full Text] [Related]
3. GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.
Tomas E; Wood JA; Stanojevic V; Habener JF
Regul Pept; 2011 Aug; 169(1-3):43-8. PubMed ID: 21549160
[TBL] [Abstract][Full Text] [Related]
4. Bariatric surgery - time to replace with GLP-1?
Webb DL; Abrahamsson N; Sundbom M; Hellström PM
Scand J Gastroenterol; 2017; 52(6-7):635-640. PubMed ID: 28276830
[TBL] [Abstract][Full Text] [Related]
5. Neuro-modulation and bariatric surgery for type 2 diabetes mellitus.
Spector D; Shikora S
Int J Clin Pract Suppl; 2010 Feb; (166):53-8. PubMed ID: 20377665
[TBL] [Abstract][Full Text] [Related]
6. Anorexigenic effects of GLP-1 and its analogues.
Gallwitz B
Handb Exp Pharmacol; 2012; (209):185-207. PubMed ID: 22249815
[TBL] [Abstract][Full Text] [Related]
7. Impact of glucagon-like peptide-1 on endothelial function.
Sjöholm A
Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():19-25. PubMed ID: 19878258
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies.
Chilton R; Wyatt J; Nandish S; Oliveros R; Lujan M
Am J Med; 2011 Jan; 124(1 Suppl):S35-53. PubMed ID: 21194579
[TBL] [Abstract][Full Text] [Related]
9. Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk.
Mannucci E; Rotella CM
Nutr Metab Cardiovasc Dis; 2008 Nov; 18(9):639-45. PubMed ID: 18849155
[TBL] [Abstract][Full Text] [Related]
10. Obesity and weight management in the elderly: a focus on men.
Han TS; Wu FC; Lean ME
Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):509-25. PubMed ID: 24054928
[TBL] [Abstract][Full Text] [Related]
11. Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like Peptide-1.
Cani PD; Neyrinck AM; Maton N; Delzenne NM
Obes Res; 2005 Jun; 13(6):1000-7. PubMed ID: 15976142
[TBL] [Abstract][Full Text] [Related]
12. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS.
van Bloemendaal L; Ten Kulve JS; la Fleur SE; Ijzerman RG; Diamant M
J Endocrinol; 2014 Apr; 221(1):T1-16. PubMed ID: 24323912
[TBL] [Abstract][Full Text] [Related]
13. The effect of bariatric surgery on gut hormones that alter appetite.
Pournaras DJ; Le Roux CW
Diabetes Metab; 2009 Dec; 35(6 Pt 2):508-12. PubMed ID: 20152735
[TBL] [Abstract][Full Text] [Related]
14. Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes.
Sesti G
Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():4-10. PubMed ID: 19878256
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
Lugari R; Dei Cas A; Ugolotti D; Barilli AL; Camellini C; Ganzerla GC; Luciani A; Salerni B; Mittenperger F; Nodari S; Gnudi A; Zandomeneghi R
Horm Metab Res; 2004 Feb; 36(2):111-5. PubMed ID: 15002062
[TBL] [Abstract][Full Text] [Related]
16. GLP-1 playing the role of a gut regulatory compound.
Hellström PM
Acta Physiol (Oxf); 2011 Jan; 201(1):151-6. PubMed ID: 20518750
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases.
Zoicas F; Droste M; Mayr B; Buchfelder M; Schöfl C
Eur J Endocrinol; 2013 May; 168(5):699-706. PubMed ID: 23392214
[TBL] [Abstract][Full Text] [Related]
18. Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes.
Herzlinger S; Horton ES
Diabetes Res Clin Pract; 2013 Apr; 100(1):1-10. PubMed ID: 23332049
[TBL] [Abstract][Full Text] [Related]
19. Incretins and other peptides in the treatment of diabetes.
Todd JF; Bloom SR
Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
[TBL] [Abstract][Full Text] [Related]
20. [Glucagon-like peptide-1 analogues and cardiovascular risk factors: evidence from clinical trials].
Mannucci E
G Ital Cardiol (Rome); 2010 Dec; 11(12 Suppl 2):26S-29S. PubMed ID: 21361053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
